Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | Chief Financial Officer | May 23, 2025 | May 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rani Therapeutics Holdings, Inc.
Report date May 23, 2025 · Filed May 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2035-05-22 | Direct | 325,000 |
Reported balance
After 2025-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-23 · Grant · Acquired 325,000 · Balance 325,000 F1: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from May 23, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from May 23, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2025 Filed May 23, 2025 17:58 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000950170-25-077180 · ownership.xml · derivative · entry 1 Sanford Svai S · CIK 0001591411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,000 Underlying: Class A Common Stock · 325,000 shares Expires 2035-05-22 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from May 23, 2025. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 21:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 323,500 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000950170-24-035570 · ownership.xml · derivative · entry 1 Sanford Svai S · CIK 0001591411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,500 Underlying: Class A Common Stock · 323,500 shares Expires 2034-03-20 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 21, 2024. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 83,724 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071474 · ownership.xml · derivative · entry 6 Sanford Svai S · CIK 0001591411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,724 Underlying: Class A Common Stock · 83,724 shares Expires 2031-07-28 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F5 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from June 17, 2021. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 83,724 | Not disclosed Strike: $9.44 | Not disclosed |
DisclosureSEC source: 0000950170-23-071474 · ownership.xml · derivative · entry 5 Sanford Svai S · CIK 0001591411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,788 Underlying: Class A Common Stock · 83,724 shares Expires 2031-07-28 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F2 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F5 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from June 17, 2021. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 58,334 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071474 · ownership.xml · derivative · entry 4 Sanford Svai S · CIK 0001591411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,334 Underlying: Class A Common Stock · 58,334 shares Expires 2032-03-21 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 58,334 | Not disclosed Strike: $13.21 | Not disclosed |
DisclosureSEC source: 0000950170-23-071474 · ownership.xml · derivative · entry 3 Sanford Svai S · CIK 0001591411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,666 Underlying: Class A Common Stock · 58,334 shares Expires 2032-03-21 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F2 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022. F2 · balance_after: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 171,500 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071474 · ownership.xml · derivative · entry 2 Sanford Svai S · CIK 0001591411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,500 Underlying: Class A Common Stock · 171,500 shares Expires 2033-03-26 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 171,500 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0000950170-23-071474 · ownership.xml · derivative · entry 1 Sanford Svai S · CIK 0001591411 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,300 Underlying: Class A Common Stock · 171,500 shares Expires 2033-03-26 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023. F2 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F2 · balance_after: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 21:06 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 205,800 | $0.00 Strike: $5.44 | $0.00 |
DisclosureSEC source: 0001415889-23-005596 · form4-03302023_010356.xml · derivative · entry 2 Sanford Svai S · CIK 0001591411 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,800 Underlying: Class A Common Stock · 205,800 shares Expires 2033-03-26 F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 21:06 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantClass A Common Stock | 139,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005596 · form4-03302023_010356.xml · nonDerivative · entry 1 Sanford Svai S · CIK 0001591411 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,597 F1 · date: The shares subject to the restricted stock unit grant vest as follows: 1/16th of the RSUs shall vest quarterly over four years from March 27, 2023. Read SEC document |
| March 22, 2023 Filed Mar 24, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Tax withholdingClass A Common Stock | 3,355 | $5.95 | $19,962.25 |
DisclosureSEC source: 0000899243-23-009587 · doc4.xml · nonDerivative · entry 1 Sanford Svai S · CIK 0001591411 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,597 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 22, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the restricted stock units granted to Mr. Sanford on March 22, 2022. F2 · balance_after: Includes 2,214 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 1, 2022. Read SEC document |
| September 09, 2022 Filed Sep 13, 2022 20:44 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Tax withholdingClass A Common Stock | 18,362 | $9.89 | $181,600.18 |
DisclosureSEC source: 0001209191-22-049802 · doc4.xml · nonDerivative · entry 1 Sanford Svai S · CIK 0001591411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,738 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on September 9, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the restricted stock units granted to Mr. Sanford on September 9, 2021. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 21:08 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $13.21 | $0.00 |
DisclosureSEC source: 0001209191-22-021021 · doc4.xml · derivative · entry 2 Sanford Svai S · CIK 0001591411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Class A Common Stock · 100,000 shares Expires 2032-03-21 F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 21:08 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantClass A Common Stock | 32,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021021 · doc4.xml · nonDerivative · entry 1 Sanford Svai S · CIK 0001591411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,100 F1 · deemedExecutionDate: The shares subject to the restricted stock unit grant vest as follows: 25% of the RSUs shall vest yearly over four years from March 22, 2022. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 20:08 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantClass A Common Stock | 106,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-055777 · doc4.xml · nonDerivative · entry 1 Sanford Svai S · CIK 0001591411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,200 F1 · deemedExecutionDate: The shares subject to the restricted stock unit grant vest as follows: 50% of the RSUs shall vest on September 9, 2022, and 50% shall vest on September 9, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.